Paradigm Biocapital Advisors’s Veradermics Inc MANE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MANE Stock Details MANE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.2M	Buy	+525,000	New	+$26.5M	0.68%	27

Other funds holding MANE

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Paradigm Biocapital Advisors's MANE Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Veradermics Inc (MANE) in Q1 2026: 525,000 shares worth $33.2M. The stake represents 0.68% of the portfolio and ranks #27 among its holdings.

81 funds tracked by Wall St. Rank hold MANE as of Q1 2026.

Paradigm Biocapital Advisors held 525,000 shares of Veradermics Inc worth $33.2M as of Q1 2026.
Veradermics Inc was a new Paradigm Biocapital Advisors position in Q1 2026.
Veradermics Inc made up 0.68% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #27 holding.
81 funds tracked by Wall St. Rank held Veradermics Inc as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.